secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001034842-26-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q4 net product sales $65.4M record; full year net income $367M, includes $245.9M tax benefit
--------------------------------------------------------------------------------

- Q4 2025 net product sales $65.4M (+41% YoY); TAVALISSE $45.6M (+47%), GAVRETO $10.2M (+27%), REZLIDHIA $9.6M (+29%).
- Full year 2025 net product sales $232M (+60% YoY); total revenue $294.3M.
- Q4 net income $268.1M ($14.72 basic EPS) includes $245.9M non-cash deferred tax benefit; FY net income $367M.
- 2026 guidance: total revenue $275-290M, net product sales $255-265M, expects positive net income.
- Cash $155.0M at Dec 31, 2025 vs $77.3M at Dec 31, 2024; R289 dose expansion enrollment on track for H2 2026 RP2D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000016/0001034842-26-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000016/rigl-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001034842-26-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer